Vladimir B. Seplyarskiy

Vladimir B. Seplyarskiy

Auto-generated profile, based on publicly available information

Vladimir B. Seplyarskiy

Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2016 in Genome Research
Verified
Journal Article
Open access
PDF file
VSVladimir B. Seplyarskiy
Vladimir B. Seplyarskiy
RSRuslan A. Soldatov
Ruslan A. Soldatov
KPKonstantin Y. Popadin
Konstantin Y. Popadin
SAStylianos E. Antonarakis
Stylianos E. Antonarakis
GBGeorgii A. Bazykin
Georgii A. Bazykin
SNSergey I. Nikolaev
Sergey I. Nikolaev
APOBEC3A and APOBEC3B, cytidine deaminases of the APOBEC family, are among the main factors causing mutations in human cancers. APOBEC deaminates cytosines in single-stranded DNA (ssDNA). A fraction of the APOBEC-induced mutations occur as clusters (“kataegis”) in single-stranded DNA produced during repair of double-stranded breaks (DSBs). However, the properties of the remaining 87% of nonclustered APOBEC-induced mutations, the source and the genomic distribution of the ssDNA where they occur, are largely unknown. By analyzing genomic and exomic cancer databases, we show that >33% of dispersed APOBEC-induced mutations occur on the lagging strand during DNA replication, thus unraveling the major source of ssDNA targeted by APOBEC in cancer. Although methylated cytosine is generally more mutation-prone than nonmethylated cytosine, we report that methylation reduces the rate of APOBEC-induced mutations by a factor of roughly two. Finally, we show that in cancers with extensive APOBEC-induced mutagenesis, there is almost no increase in mutation rates in late replicating regions (contrary to other cancers). Because late-replicating regions are depleted in exons, this results in a 1.3-fold higher fraction of mutations residing within exons in such cancers. This study provides novel insight into the APOBEC-induced mutagenesis and describes the peculiarity of the mutational processes in cancers with the signature of APOBEC-induced mutations.

27 August 2021 in Science
Verified
Journal Article
Closed access
VSVladimir B. Seplyarskiy
Vladimir B. Seplyarskiy
RSRuslan A. Soldatov
Ruslan A. Soldatov
EKEvan Koch
Evan Koch
RMRyan J. McGinty
Ryan J. McGinty
JGJakob M. Goldmann
Jakob M. Goldmann
SSShamil Sunyaev
Shamil Sunyaev
Gauging the spectrum of human mutations: It has become increasing clear that mutation affects phenotypic variation and disease risk across humans. However, there are many different types of mutation. Seplyarskiy et al . applied a matrix factorization method to large human genomic datasets to identify germline mutational processes in an unsupervised manner. From this survey, nine robust mutational components were identified and specific mechanisms generating seven of these processes are proposed from correlations with genomic features. These results confirm and improve upon our understanding of mutational processes and reveal likely mechanisms of mutation in the human genome. —LMZ

30 November 2023 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
VSVladimir Seplyarskiy
Vladimir Seplyarskiy
EKEvan M. Koch
Evan M. Koch
DLDaniel J. Lee
Daniel J. Lee
JLJoshua S. Lichtman
Joshua S. Lichtman
HLHarding H. Luan
Harding H. Luan
SSShamil R. Sunyaev
Shamil R. Sunyaev

9 December 2016 in Genome Research
Verified
Journal Article
Open access
PDF file
VSVladimir B. Seplyarskiy
Vladimir B. Seplyarskiy
MAMaria A. Andrianova
Maria A. Andrianova
GBGeorgii A. Bazykin
Georgii A. Bazykin
APOBEC3A/B cytidine deaminase is responsible for the majority of cancerous mutations in a large fraction of cancer samples. However, its role in heritable mutagenesis remains very poorly understood. Recent studies have demonstrated that both in yeast and in human cancerous cells, most APOBEC3A/B-induced mutations occur on the lagging strand during replication and on the nontemplate strand of transcribed regions. Here, we use data on rare human polymorphisms, interspecies divergence, and de novo mutations to study germline mutagenesis and to analyze mutations at nucleotide contexts prone to attack by APOBEC3A/B. We show that such mutations occur preferentially on the lagging strand and on nontemplate strands of transcribed regions. Moreover, we demonstrate that APOBEC3A/B-like mutations tend to produce strand-coordinated clusters, which are also biased toward the lagging strand. Finally, we show that the mutation rate is increased 3′ of C→G mutations to a greater extent than 3′ of C→T mutations, suggesting pervasive trans-lesion bypass of the APOBEC3A/B-induced damage. Our study demonstrates that 20% of C→T and C→G mutations in the TpCpW context—where W denotes A or T, segregating as polymorphisms in human population—or 1.4% of all heritable mutations are attributable to APOBEC3A/B activity.

11 October 2024 in Science
Verified
Journal Article
Open access
EMEduardo A. Maury
Eduardo A. Maury
AJAttila Jones
Attila Jones
VSVladimir Seplyarskiy
Vladimir Seplyarskiy
TNThanh Thanh L. Nguyen
Thanh Thanh L. Nguyen
CRChaggai Rosenbluh
Chaggai Rosenbluh
ACAndrew Chess
Andrew Chess
Germline mutations modulate the risk of developing schizophrenia (SCZ). Much less is known about the role of mosaic somatic mutations in the context of SCZ. Deep (239×) whole-genome sequencing (WGS) of brain neurons from 61 SCZ cases and 25 controls postmortem identified mutations occurring during prenatal neurogenesis. SCZ cases showed increased somatic variants in open chromatin, with increased mosaic CpG transversions (CpG>GpG) and T>G mutations at transcription factor binding sites (TFBSs) overlapping open chromatin, a result not seen in controls. Some of these variants alter gene expression, including SCZ risk genes and genes involved in neurodevelopment. Although these mutational processes can reflect a difference in factors indirectly involved in disease, increased somatic mutations at developmental TFBSs could also potentially contribute to SCZ.

8 October 2025 in Nature
Verified
Journal Article
Open access
PDF file
VSVladimir Seplyarskiy
Vladimir Seplyarskiy
MMMikhail A. Moldovan
Mikhail A. Moldovan
EKEvan Koch
Evan Koch
PKPrathitha Kar
Prathitha Kar
MNMatthew D. C. Neville
Matthew D. C. Neville
SSShamil Sunyaev
Shamil Sunyaev
In renewing tissues, mutations conferring selective advantage may result in clonal expansions 1–4 . In contrast to somatic tissues, mutations driving clonal expansions in spermatogonia (CES) are also transmitted to the next generation. This results in an effective increase of de novo mutation rate for CES drivers 5–8 . CES was originally discovered through extreme recurrence of de novo mutations causing Apert syndrome 5 . Here, we develop a systematic approach to discover CES drivers as hotspots of human de novo mutation. Our analysis of 54,715 trios ascertained for rare conditions 9–13 , 6,065 control trios 12,14–19 and population variation from 807,162 mostly healthy individuals 20 identifies genes manifesting rates of de novo mutations inconsistent with plausible models of disease ascertainment. We propose 23 genes hypermutable at loss-of-function (LoF) sites as candidate CES drivers. An extra 17 genes feature hypermutable missense mutations at individual positions, suggesting CES acting through gain of function. CES increases the average mutation rate roughly 17-fold for LoF genes in both control trios and sperm and roughly 500-fold for pooled gain-of-function sites in sperm 21 . Positive selection in the male germline elevates the prevalence of genetic disorders and increases polymorphism levels, masking the effect of negative selection in human populations. Despite the excess of mutations in disease cohorts for 19 LoF CES driver candidates, only 9 show clear evidence of disease causality 22 , suggesting that CES may lead to false-positive disease associations.